BDX Stock Analysis: Becton Dickinson | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 58.168m USD | 12M Return: 55.7% | US0758871091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 330M
EPS Trend: 50.5%
Qual. Beats: 0
Rev. Trend: 64.6%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Becton, Dickinson and Company (BDX) is a large-cap U.S. medical technology company that develops, manufactures, and sells a broad portfolio of medical supplies, devices, laboratory instruments, and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public worldwide. The company operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional and Life Sciences.
Its product offerings span vascular access and infusion therapy products (IV catheters, central lines, needle-free connectors, infusion systems, pharmacy automation), drug delivery systems (prefillable syringes, closed-system drug transfer devices), diagnostics (automated blood and TB culturing, molecular testing, microbiology lab automation, clinical oncology and immunology reagents), life science research tools (flow cytometers, single-cell gene expression solutions), and surgical and interventional products (hernia and soft tissue repair, biosurgery, peripheral intervention, urology). BDX also maintains a strategic collaboration with ChemoGLO to advance hazardous drug contamination testing in healthcare settings.
As a diversified medical device manufacturer, BDX benefits from cross-selling opportunities across its four segments and a recurring revenue base driven by high-volume consumables such as syringes, needles, and blood collection products. The medical device industry is characterized by lengthy regulatory approval cycles, significant R&D investment, and stable demand tied to healthcare utilization rather than economic cycles. BDXs segment structure allows it to participate across the full continuum of care, from pharmaceutical development and bioprocessing through clinical diagnostics, drug delivery, and surgical intervention.
- Connected Care medication management revenue accelerates on hospital automation demand
- Interventional segment margins pressured by post-pandemic elective procedure normalization
- Prefillable syringe demand surges from GLP-1 obesity drug manufacturers
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.70 > 1.0 |
| NWC/Revenue: -5.38% < 20% (prev 4.31%; Δ -9.69% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.48b > Net Income 1.14b |
| Net Debt (13.6b) to EBITDA (4.74b): 2.88 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (274.1m) vs 12m ago -4.55% < -2% |
| Gross Margin: 47.01% > 18% (prev 45.44%; Δ 1.56% > 0.5%) |
| Asset Turnover: 38.11% > 50% (prev 39.47%; Δ -1.36% > 0%) |
| Interest Coverage Ratio: 4.83 > 6 (EBIT TTM 2.50b / Interest Expense TTM 518.0m) |
| A: -0.02 (Total Current Assets 8.32b - Total Current Liabilities 9.40b) / Total Assets 50.8b |
| B: 0.34 (Retained Earnings 17.5b / Total Assets 50.8b) |
| C: 0.05 (EBIT TTM 2.50b / Avg Total Assets 53.1b) |
| D: 3.07 (Book Value of Equity 50.8b / Total Liabilities 16.6b) |
| Altman-Z'' = 4.52 = AA |
| DSRI: 1.00 (Receivables 2.77b/2.99b, Revenue 20.2b/21.8b) |
| GMI: 0.97 (GM 45.44% / 47.01%) |
| AQI: 1.01 (AQ_t 0.71 / AQ_t-1 0.71) |
| SGI: 0.93 (Revenue 20.2b / 21.8b) |
| TATA: -0.05 (NI 1.14b - CFO 3.48b) / TA 50.8b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of November 07, 2026, the stock is trading at USD 211.88 with a total of 2,172,540 shares traded. Over the past week, the price has changed by +7.07%, over one month by +17.52%, over three months by +20.36% and over the past year by +55.73%.
Current recommended Stop Loss: 206.50 (which is 2.5% or 1.2 ATR below the current price).
Becton Dickinson has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy BDX.
- StrongBuy: 7
- Buy: 1
- Hold: 7
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 195.6 | -7.7% |
P/E Trailing = 48.6447
P/E Forward = 15.7233
P/S = 2.5871
P/B = 2.3337
P/EG = 1.1074
Revenue TTM = 20.2b USD
EBIT TTM = 2.50b USD
EBITDA TTM = 4.74b USD
Long Term Debt = 13.5b USD (from longTermDebt, two quarters ago)
Short Term Debt = 944.0m USD (from shortTermDebt, last quarter)
Debt = 14.4b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.6b USD (calculated: Debt 14.4b - CCE 733.0m)
Enterprise Value = 71.8b USD (58.2b + Debt 14.4b - CCE 733.0m)
Interest Coverage Ratio = 4.83 (Ebit TTM 2.50b / Interest Expense TTM 518.0m)
EV/FCF = 25.56x (Enterprise Value 71.8b / FCF TTM 2.81b)
FCF Yield = 3.91% (FCF TTM 2.81b / Enterprise Value 71.8b)
FCF Margin = 13.89% (FCF TTM 2.81b / Revenue TTM 20.2b)
Net Margin = 5.66% (Net Income TTM 1.14b / Revenue TTM 20.2b)
Gross Margin = 47.01% ((Revenue TTM 20.2b - Cost of Revenue TTM 10.7b) / Revenue TTM)
Gross Margin QoQ = 51.06% (prev 46.46%)
Tobins Q-Ratio = 1.41 (Enterprise Value 71.8b / Total Assets 50.8b)
Interest Expense / Debt = 3.61% (Interest Expense 518.0m / Debt 14.4b)
Taxrate = 24.89% (493.0m / 1.98b)
NOPAT = 1.88b (EBIT 2.50b * (1 - 24.89%))
Current Ratio = 0.88 (Total Current Assets 8.32b / Total Current Liabilities 9.40b)
Debt / Equity = 0.28 (Debt 14.4b / totalStockholderEquity, last quarter 50.8b)
Debt / EBITDA = 2.88 (Net Debt 13.6b / EBITDA 4.74b)
Debt / FCF = 4.85 (Net Debt 13.6b / FCF TTM 2.81b)
Total Stockholder Equity = 31.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.16% (Net Income 1.14b / Total Assets 50.8b)
RoE = 3.67% (Net Income TTM 1.14b / Total Stockholder Equity 31.2b)
RoCE = 5.60% (EBIT 2.50b / Capital Employed (Equity 31.2b + L.T.Debt 13.5b))
RoIC = 3.75% (NOPAT 1.88b / Invested Capital 50.1b)
WACC = 5.76% (E(58.2b)/V(72.5b) * Re(6.51%) + D(14.4b)/V(72.5b) * Rd(3.61%) * (1-Tc(0.25)))
Discount Rate = 6.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.94 | Cagr: -2.52%
[DCF] Terminal Value 76.10% ; FCFF base≈2.75b ; Y1≈2.88b ; Y5≈3.32b
[DCF] Fair Price = 138.1 (EV 51.3b - Net Debt 13.6b = Equity 37.6b / Shares 272.4m; r=8.35% [WACC [floored]]; 5y FCF grow 5.21% → 2.50% )
EPS Correlation: 50.48 | EPS CAGR: 3.44% | SUE: 0.66 | # QB: 0
Revenue Correlation: 64.57 | Revenue CAGR: 2.89% | SUE: 2.81 | # QB: 2
EPS current Quarter (2026-12-31): EPS=2.73 | Chg30d=+0.04% | Revisions=+25% | Analysts=11
EPS next Quarter (2027-03-31): EPS=3.05 | Chg30d=-0.24% | Revisions=+25% | Analysts=11
EPS current Year (2027-09-30): EPS=13.30 | Chg30d=+0.07% | Revisions=+50% | GrowthEPS=+4.7% | GrowthRev=+1.4%
EPS next Year (2028-09-30): EPS=14.18 | Chg30d=+0.03% | Revisions=+25% | GrowthEPS=+6.6% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: +67% (up=6, down=0)